A ready-to-use liquid glucagon for treatment of severe hypoglycemia demonstrates reduced healthcare payer costs in a budget impact model

References

• Diabetes Control and Complications Trial (DCCT) Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45(10):1289–1298.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial (DCCT) Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997;46(2):271–286.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187–192.
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J. 2000;321(7258):405–412.
   PubMed Web of Science ®Google Scholar
• Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet. 1993;341(8856):1306–1309.
   PubMed Web of Science ®Google Scholar
• Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes. Diabetic Med. 2008;25(3):245–254.
   PubMed Web of Science ®Google Scholar
• Clarke W, Jones T, Rewers A, et al. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. 2009;10(12):134–145.
   PubMedGoogle Scholar
• Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26(6):1902–1912.
   PubMed Web of Science ®Google Scholar
• Cryer PE. Hierarchy of physiological responses to hypoglycemia: relevance to clinical hypoglycemia in type I (insulin dependent) diabetes mellitus. Horm Metab Res. 1997;29(03):92–96.
   PubMedGoogle Scholar
• Laing SP, Swerdlow AJ, Slater SD, et al. The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med. 1999;16(6):466–471.
   PubMed Web of Science ®Google Scholar
• Campbell IW. Metformin and the sulphonylureas: the comparative risk. Horm Metab Res Suppl. 1985;15:105–111.
   PubMedGoogle Scholar
• Williams SA, Shi L, Brenneman SK, et al. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diab Comp. 2012;26(5):399–406.
   Google Scholar
• Haymond MW, Liu J, Bispham J, et al. Inadequate use of glucagon in patients with type 1 diabetes. Clin Diab. 2018;67(1):383-P.
   Google Scholar
• Mitchell BD, He X, Sturdy IM, et al. Glucagon prescription patterns in patients with either type 1 or 2 diabetes with newly prescribed insulin. Endocrine Pract. 2016;22(2):123–135.
   PubMed Web of Science ®Google Scholar
• GlucaGen® (glucagon [rDNA origin] for injection) Hypokit® Instructions for Use. Novo Nordisk A/S. 25 April 2014.
   Google Scholar
• Valentine V, Newswanger B, Prestrelski S, et al. Human factors usability and validation studies of a glucagon autoinjector in a simulated severe hypoglycemia rescue situation. Diab Tech & Therap. 2019;21(9):522–530.
   PubMed Web of Science ®Google Scholar
• Newswanger B, Prestrelski S, Andre AD. Human factors studies of a prefilled syringe with stable liquid glucagon in a simulated severe hypoglycemia rescue situation. Expert Opin Drug Deliv. 2019;16(9):1015–1025.
   PubMed Web of Science ®Google Scholar
• Yale JF, Dulude H, Egeth M, et al. Faster use and fewer failures with needle-free nasal glucagon versus injectable glucagon in severe hypoglycemia rescue: a simulation study. Diabetes Technol Ther. 2017;19(7):423–432.
   PubMed Web of Science ®Google Scholar
• Eldrick H, Witten TA, Arai Y. Glucagon treatment of insulin reactions. N Engl J Med. 1958;258:476–480.
   PubMed Web of Science ®Google Scholar
• Vukmir RB, Paris PM, Yealy DM. Glucagon: prehospital therapy for hypoglycemia. Ann Emerg Med. 1991;20(4):375–379.
   PubMed Web of Science ®Google Scholar
• Steel JM, Allwinkle J, Moffat R, et al. Use of Lucozade and glucagon by ambulance staff for treating hypoglycemia. Br Med J. 1992;304(6837):1283–1284.
   PubMedGoogle Scholar
• Patrick AW, Collier A, Hepburn A, et al. Comparison of intramuscular glucagon and intravenous dextrose in the treatment of hypoglycemia coma in an accident and emergency department. Arch Emerg Med. 1990;7(2):73–77.
   PubMedGoogle Scholar
• Carstens S, Sprehn M. Prehospital treatment of severe hypoglycaemia: a comparison of intramuscular glucagon and intravenous glucose. Prehosp Disaster Med. 1998;13(2–4):44–50.
   PubMedGoogle Scholar
• Namba M, Hanafusa T, Kono N, et al. Clinical evaluation of biosynthetic glucagon treatment for recovery from hypoglycemia developed in diabetic patients. Diabetes Res Clin Pract. 1993;19(2):133–138.
   PubMed Web of Science ®Google Scholar
• Northam EA, Anderson PJ, Jacobs R, et al. Neuropsychological profiles in children with type 1 diabetes 6 years after disease onset. Diabetes Care. 2001;24(9):1541–1546.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Glycemic targets: standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Suppl 1):S66–S76.
   PubMed Web of Science ®Google Scholar
• Ratzki-Leewing A, Harris SB, Mequanint S, et al. Real-world crude incidence of hypoglycemia in adults with diabetes: results of the InHypo-DM study, Canada. BMJ Open Diab Res Care. 2018;6(1):e000503.
   PubMed Web of Science ®Google Scholar
• Kedia N. Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach. Diabetes Metab Syndr Obes. 2011;4:337–346.
   PubMedGoogle Scholar
• Polonsky WH, Fisher L, Hessler D, et al. Investigating hypoglycemic confidence in type 1 and type 2 diabetes. Diabetes Technol Ther. 2017;19(1):1–6.
   PubMedGoogle Scholar
• Seaquist ER, Dulude H, Zhang XM, et al. A prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycemia in adults with type 1 diabetes in a real-world setting. Diabetes Obes Metab. 2018;20(5):1316–1320.
   PubMed Web of Science ®Google Scholar
• Deeb LC, Dulude H, Guzman CB, et al. A phase 3 multicenter, open-label prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting. Pediatr Diabetes. 2018;19(5):1007–1013.
   PubMed Web of Science ®Google Scholar
• Diabetes Age and Sex Composition: 2010. 2010 Census Briefs [Internet]. U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau; Washington, DC; [cited 2014 Aug 26]. Available from: http://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf.
   Google Scholar
• National Diabetes Statistics Report, 2013. Estimates of Diabetes and Its Burden in the United States [Internet]. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; Washington, DC; [cited 2014 Aug 26; 2019 Jun 30]. Available from: http://www.cdc.gov/Diabetes/pubs/estimates11.htm#6; https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf.
   Google Scholar
• Li C, Ford ES, Zhao G, et al. Trends of insulin use among US adults with type 2 diabetes: the behavioral risk factor surveillance system, 1995–2007. J Diab Complicat. 2012;26(1):17–22.
   PubMed Web of Science ®Google Scholar
• Frier BM. The incidence and impact of hypoglycemia in type 1 and type 2 diabetes. Int Diab Mon. 2009;21(6):210–218.
   Google Scholar
• Edridge CL, Dunkley AJ, Bodicoat DH, et al. Prevalence and incidence of hypoglycemia in 532,542 people with type 2 diabetes on oral therapies and insulin: a systematic review and meta-analysis of population based studies. PLoS One. 2015;10(6):e0126427.
   PubMed Web of Science ®Google Scholar
• Ginde AA, Espinola JA, Camargo CA. Trends and disparities in U.S. emergency department visits for hypoglycemia, 1993–2005. Diabetes Care. 2008;31(3):511–513.
   PubMed Web of Science ®Google Scholar
• Parsaik AK, Carter RE, Pattan V, et al. Population-based study of severe hypoglycemia requiring emergency medical service assistance reveals unique findings. J Diabetes Sci Technol. 2012;6(1):65–73.
   PubMedGoogle Scholar
• 2018 Medicare Fee Schedules. U.S. Centers for Medicare and Medicaid Services; Baltimore, MD; [cited 2018 Apr 9]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/FeeScheduleGenInfo/index.html.
   Google Scholar